对美国处方开具情况的重新思考。
Rethinking prescribing in the United States.
作者信息
Ellner Andrew
机构信息
BMJ Knowledge, London WC1H 9JR.
出版信息
BMJ. 2003 Dec 13;327(7428):1397-400. doi: 10.1136/bmj.327.7428.1397.
Abstract
The United States wants to increase senior citizens' access to prescription drugs at a time when spending on drugs is soaring. Is a national list of essential medicines the answer?
摘要
在美国药品支出飙升之际，美国希望增加老年人获得处方药的机会。一份全国性的基本药物清单会是答案吗？
相似文献
1
Rethinking prescribing in the United States.对美国处方开具情况的重新思考。
BMJ. 2003 Dec 13;327(7428):1397-400. doi: 10.1136/bmj.327.7428.1397.
2
GP fundholding and the costs of prescribing.
J Public Health Med. 1995 Sep;17(3):323-9.
3
Prescribing data and cost comparisons in New Zealand.
N Z Med J. 1997 Nov 28;110(1056):445-6.
4
What is the impact of free drug samples on patients?免费药物样品对患者有什么影响？
South Med J. 2008 Sep;101(9):879-80. doi: 10.1097/SMJ.0b013e318180bd18.
5
Prescribing costs.
N Z Med J. 1998 Mar 13;111(1061):83.
6
The rising cost of pharmaceuticals: a physician's perspective.
Am J Hosp Pharm. 1993 Aug;50(8 Suppl 4):S8-10.
7
8
Scottish GPs prescribe more now but spend less.苏格兰的全科医生现在开的药更多了，但花费却更少了。
BMJ. 2013 Jan 24;346:f539. doi: 10.1136/bmj.f539.
9
[Economic prescription of drugs].[药物的经济学处方]
Ugeskr Laeger. 2004 Apr 26;166(18):1695.
10
Trends in prescribing in primary care in Croatia, 2000-2012: prescribing volume, costs and regulatory measures.
Coll Antropol. 2014 Dec;38 Suppl 2:67-72.
引用本文的文献
1
Exchanging health lessons globally.在全球范围内交流健康经验。
BMJ. 2004 Jan 31;328(7434):239-40. doi: 10.1136/bmj.328.7434.239.
本文引用的文献
1
Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.基于参考的定价方案：对药品支出、资源利用和健康结果的影响。
Pharmacoeconomics. 2002;20(9):577-91. doi: 10.2165/00019053-200220090-00002.
2
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.基于参考定价的血管紧张素转换酶抑制剂对药物利用的影响。
CMAJ. 2002 Mar 19;166(6):737-45.
3
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.血管紧张素转换酶抑制剂参考定价的结果
N Engl J Med. 2002 Mar 14;346(11):822-9. doi: 10.1056/NEJMsa003087.
4
The prescription-drug problem.处方药问题。
N Engl J Med. 2002 Mar 14;346(11):790. doi: 10.1056/NEJM200203143461102.
5
Direct-to-consumer advertising--strengthening our health care system.直接面向消费者的广告——强化我们的医疗保健系统。
N Engl J Med. 2002 Feb 14;346(7):526-8. doi: 10.1056/NEJM200202143460714.
6
Promotion of prescription drugs to consumers.向消费者推广处方药。
N Engl J Med. 2002 Feb 14;346(7):498-505. doi: 10.1056/NEJMsa012075.
7
Pharmacy benefit managers: a model for Medicare?药品福利管理机构：医疗保险的一种模式？
Issue Brief Natl Health Policy Forum. 2001 Jul 9(765):1-12.
8
Pharmacoeconomic analyses: making them transparent, making them credible.药物经济学分析：使其透明，使其可信。
JAMA. 2000 Apr 26;283(16):2158-60. doi: 10.1001/jama.283.16.2158.
9
HMO formularies and care costs.健康维护组织（HMO）的药品处方集和护理费用。
Lancet. 1996 Aug 31;348(9027):619-20. doi: 10.1016/S0140-6736(05)64839-8.
10
HMO formularies and care costs.健康维护组织（HMO）的药品处方集与护理费用。
Lancet. 1996 May 4;347(9010):1264. doi: 10.1016/s0140-6736(96)90782-5.
Zotero 插件